Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists develop vaccine for fusobacterium necrophorum
Fusobacterium necrophorum causes infection in livestock and people, but scientists at Kansas State University have found a way to protect animals and humans from the virus.

Bacterium affects both livestock and people

A vaccine that could provide effective, antibiotic-free prevention of Fusobacterium infection has been developed by scientists at Kansas State University.

Fusobacterium necrophroum infection affects both livestock and people. Currently, antibiotics are used to control the bacterium, but researchers say the new vaccine takes an altogether different approach.

"The Food and Drug Administration has prevented the use of many antibiotics in cattle, especially those similar to ones with human applications, so this vaccine is an alternative,” commented Sanjeev K. Narayanan, professor of diagnostic medicine and pathobiology. 

“This way, we don't expose people's food to as many antibiotics, so the vaccine protects both animals and humans."

The vaccine uses a two-pronged approach. It first immunises the animal against leukotoxins, which kill white blood cells and Kupffer cells - the liver’s natural weapons against bacteria.

The team found that Fusobacterium bacterium is able to survive in the liver because it produces leukotoxins. By immunising, if the bacterium enters the liver, there are antibodies built up against it, and the antibodies will neutralise the toxin.

The second element of the vaccine was developed in the lab, where the team identified the protein that allows the bacterium to attach to the walls of the rumen and the liver.

They were then able to identify a major protein in Fusobacterium necrophorum that is responsible for attaching to organs. Antibodies generated in the animal against the protein will prevent bacterial attachment.

"If you can prevent attachment, you can prevent infection," said T.G Nagaraja, a distinguished professor of microbiology. "That's why this patented vaccine uses a two-pronged approach."

The team says the vaccine is currently in testing for cattle, and may eventually be available also for sheep and for people.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.